Roche provides update on Alzheimer ’s Prevention Initiative study evaluating crenezumab in autosomal dominant Alzheimer’s disease

Crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer ’s diseaseFor more than a decade Roche has been working in collaboration with Banner Alzheimer ’s Institute, the University of Antioquia in Colombia and the National Institute on Aging on this pioneering prevention studyInitial data will be presented at the upcoming Alzheimer ' s Association International ConferenceBasel, 16 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), together with Banner Alzheimer ’s Institute, today announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer ' s Disease (ADAD) Colombia Trial. The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimer ’s disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimer’s disease. The trial did not demonstrate a statistically significant clinical benefit in either of its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function, measured by the API ADAD composite cognitive score and the Free and Cued Selective Reminding Test (FCSRT) Cueing Index, respectively.Small numerical differences favouring crenezumab were observed across the co-primary and multiple secondary and exploratory endpoints, but these were not statistically significant. No new safety issues were identified with crenezumab duri...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news